The risk of respiratory syncytial virus hospitalization (RSVH) and respiratory-related illness hospitalization (RIH) does not significantly differ between the first and second year of life in paediatric patients with haemodynamically significant congenital heart disease (HSCHD), a new study shows.
Treatment with high-dose prednisolone following intravenous administration of high-dose methylprednisolone may provide increased survival benefit in patients with acute exacerbation of idiopathic interstitial pneumonia (AE-IIP), according to a study.
Dual treatment of platinum/pemetrexed yields an improved disease-free survival (DFS) and clinical toxicity compared with other platinum-based doublet therapies for nonsquamous nonsmall cell lung cancer (NSCLC), a new study reveals.
DAR-901, an inactivated booster vaccine against tuberculosis, induces a humoral and cellular immune response against antigens, has an acceptable safety profile, and is well-tolerated, a new randomized controlled trial shows.
The BRAF inhibitors vemurafenib and dabrafenib, currently approved for use in advanced melanoma, are also effective in a subset of lung adenocarcinoma patients with BRAF mutations, according to a retrospective European trial presented at the European Lung Cancer Conference (ELCC) held in Geneva, Switzerland.
An extrafine fixed triple therapy, comprising the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB), the long-acting β₂-agonist (LABA) formoterol fumarate (FF), and the inhaled corticosteroid (ICS) beclometasone dipropionate (BDP), is superior to the LAMA tiotropium alone in reducing exacerbations and improving lung function in patients with symptomatic chronic obstructive pulmonary disease (COPD), according to the TRINITY* trial.